Business Wire

ADVA delivers unprecedented precision in timing networks with TrueTime™

Share

ADVA (FSE: ADV) today announced a new and robust way to deliver unprecedented levels of precision in timing networks. Built on ADVA’s TrueTime™ technology, this new end-to-end solution will prove key for 5G, smart grid and other time-sensitive applications. Unlike other delivery mechanisms, TrueTime™ uses PTP-optimized optical transport to provide accurate synchronization from the core of the network all the way to the edge. It does this by combining ePRTC core clocks and ultra-precise boundary clocks to ensure nanosecond timing. Not only does this method provide PRTC levels of accuracy, but it’s also more robust than any competing solution and this is key in the battle to mitigate the risk of GNSS vulnerabilities. What’s more, in greenfield deployments, TrueTime™ enables service providers to reduce the number of PRTC core clocks and GNSS equipment, simplifying network management and reducing costs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200929005114/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

ADVA’s TrueTime™ solution will prove vital for 5G, smart grid and other time-sensitive applications (Graphic: Business Wire)

“Our TrueTime™ solution addresses some of the most urgent challenges for operators of critical infrastructure. It enables highly accurate synchronization throughout the transport network and offers a future-proof way to tackle the risk of reliance on satellite-based timing. From governments concerned with the growing risk of blocked GNSS signals to mobile network operators rolling out next-generation services, our TrueTime™ technology will prove invaluable,” said Henning Hinderthür, VP, product line management, ADVA. “TrueTime™ combines our PTP-optimized FSP 3000 optical transport with our ultra-precise Oscilloquartz technology, including PTP grandmasters with ePRTC capabilities in the core and boundary clock class D technology in metro locations. This even reduces cost and complexity by eliminating the need for unnecessary equipment, enabling operators to streamline their timing infrastructure.”

ADVA TrueTime™ offers new levels of robust and precise synchronization for even the most challenging applications. It achieves this by using a bidirectional channel to deliver SyncE and PTP traffic. Accuracy is ensured by PRTC/ePRTC core clocks featuring OSA 5430/40 in combination with OSA 3230/3350 cesium atomic clocks. Closely-spaced, out-of-band wavelengths help TrueTime™ tackle asymmetric delay and leave all other channels available for customer traffic. What’s more, every element of the TrueTime™ solution is transparently controlled by ADVA’s Ensemble Controller and Ensemble Sync Director management system, featuring Syncjack™ monitoring technology. As well as being the market’s only complete end-to-end solution combining timing, transport and assurance technology, TrueTime™ offers the benefits of a fully integrated synchronization overlay solution. This empowers operators to protect their investment by harnessing rapid innovation cycles.

“All across the world, governments and businesses are realizing that network timing based on GNSS is vulnerable to failure, disruption and interference. Ensuring backup is now seen as a mandatory step towards secure synchronization. What we’re announcing today leverages two key Oscilloquartz innovations: Our boundary clocks now meet class D performance and use multiple clock domains for link redundancy, and our fully redundant ePRTC solutions utilize our new optical atomic clocks. This means that operators can ensure PRTC quality in greenfield networks without the need to invest in PRTCs at every single site,” commented Nir Laufer, senior director, product line management, Oscilloquartz, ADVA. “From our newly enhanced boundary clocks and unique optical cesium technology to the flexible ADVA FSP 3000 open line system, each element is a pre-integrated part of our TrueTime™ solution. And for ultimate efficiency and ease of use, every piece is under the management umbrella of our comprehensive Ensemble Controller and Ensemble Sync Director.”

Further information on TrueTime™ is available in these slides: https://adva.li/tt-sync-slides.

A supporting solution brief can also be downloaded: https://adva.li/tt-sync-brief.


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we're creating new opportunities for tomorrow's networks. For more information, please visit us at www.oscilloquartz.com.

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye